Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Non-Squamous Non-Small Cell Lung Cancer 4Stomach Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1Solid Cancers 1Neoplasms 1Lung Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 33Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 15Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × onartuzumab × Clear all
NCT01662869 2016-11-02

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Hoffmann-La Roche

Phase 3 Completed
564 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01590719 2016-08-09

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

Hoffmann-La Roche

Phase 2 Completed
123 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡